

List of Publications by Year in
Descending Order

Source: <https://exaly.com/author-pdf/3565096/jia-h-kao-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

634 papers	25,192 citations	73 h-index	138 g-index
728 ext. papers	28,841 ext. citations	7.3 avg, IF	7.17 L-index

#	Paper	IF	Citations
634	Response to "Iodized Oil CT-Guided Radiofrequency Ablation for Hepatocellular Carcinoma Within Milan Criteria".. <i>Hepatology International</i> , 2022 , 16, 209	8.8	
633	Long-term evolution of estimated glomerular filtration rate in patients with antiviral treatment for hepatitis C virus infection.. <i>Clinical Gastroenterology and Hepatology</i> , 2022 ,	6.9	2
632	Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Gut</i> , 2022 , 71, 176-184	19.2	4
631	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 , 7, 396-415	18.8	11
630	Letter: hepatic steatosis and fibrosis in chronic hepatitis B-the chicken-and-egg conundrum.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 , 55, 143-144	6.1	1
629	Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunities. <i>Gut</i> , 2021 ,	19.2	0
628	Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 908-918	6.1	5
627	Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multi-center, multi-ethnic cohort (RETRACT-B study). <i>Gastroenterology</i> , 2021 ,	13.3	9
626	Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 ,	6.1	1
625	Letter to the Editor: New kid in the playground: HBcrAg and risk of HCC. <i>Hepatology</i> , 2021 ,	11.2	
624	Management of Hepatitis B in Persons Who Inject Drugs (PWID). <i>Current Hepatology Reports</i> , 2021 , 20, 158	1	1
623	Artificial intelligence in precision medicine in hepatology. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 569-580	4	12
622	Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan. <i>Hepatology International</i> , 2021 , 15, 338-349	8.8	7
621	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. <i>Liver International</i> , 2021 , 41, 1265-1277	7.9	7
620	Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 2247-2254	4	1
619	Response to letter to the editor "The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma". <i>Journal of the Formosan Medical Association</i> , 2021 , 120, 1161-1164	3.2	1
618	Direct comparison of biopsy techniques for hepatic malignancies. <i>Clinical and Molecular Hepatology</i> , 2021 , 27, 305-312	6.9	3

617	Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 887-896	3.4	2
616	Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients. <i>Hepatology International</i> , 2021 , 15, 582-592	8.8	0
615	Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , 2021 , 15, 451-458	4.8	15
614	Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 2884-2892	4	0
613	Investigating the prevalence and clinical effects of hepatitis delta viral infection in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2021 , 54, 901-908	8.5	0
612	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	1
611	Reply to "Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia". <i>Journal of the Formosan Medical Association</i> , 2021 , 120, 1410-1411	3.2	
610	Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters. <i>JHEP Reports</i> , 2021 , 3, 100254	10.3	4
609	APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. <i>Hepatology International</i> , 2021 , 15, 833-851	8.8	8
608	Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. <i>Clinical and Molecular Hepatology</i> , 2021 , 27, 575-588	6.9	0
607	Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The MOSAIC study. <i>Kaohsiung Journal of Medical Sciences</i> , 2021 , 37, 245-252	2.4	1
606	Response to letter to the editor "Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy". <i>Journal of the Formosan Medical Association</i> , 2021 , 120, 915-917	3.7	
605	The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2021 , 120, 965-973	3.2	5
604	Reply to: "Sofosbuvir and the risk of kidney dysfunction". <i>Journal of Hepatology</i> , 2021 , 74, 257-258	13.4	
603	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. <i>Hepatology International</i> , 2021 , 15, 71-81	8.8	4
602	Novel Biomarkers for the Management of Chronic Hepatitis B Virus Infection 2021 , 231-250		
601	The metabolic profiles and body composition of lean metabolic associated fatty liver disease. <i>Hepatology International</i> , 2021 , 15, 405-412	8.8	3
600	One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. <i>Hepatology International</i> , 2021 , 15, 105-113	8.8	0

599	Clinical manifestations and outcomes of patients with scirrhous hepatocellular carcinoma. <i>Hepatology International</i> , 2021 , 15, 472-481	8.8	2
598	Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2021 , 27, 524-534	6.9	3
597	Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan. <i>Journal of Hepatology</i> , 2021 , 75, 132-141	13.4	3
596	Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>Hepatology International</i> , 2021 , 15, 1109-1121	8.8	0
595	Iodized oil computed tomography versus ultrasound-guided radiofrequency ablation for early hepatocellular carcinoma. <i>Hepatology International</i> , 2021 , 15, 1247-1257	8.8	3
594	Management of non-alcoholic fatty liver disease in patients with sarcopenia. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 1-13	4	
593	Paradigm shift in the treatment options of hepatocellular carcinoma. <i>Liver International</i> , 2021 ,	7.9	3
592	ssHepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicenter cohort study. <i>Liver International</i> , 2021 ,	7.9	0
591	Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan.. <i>Infectious Diseases and Therapy</i> , 2021 , 11, 485	6.2	0
590	Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. <i>Scientific Reports</i> , 2021 , 11, 23473	4.9	1
589	Letter: elevated HBV DNA predicts poor survival in hepatocellular carcinoma after hepatic resection-authorsNepley. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 203-204	6.1	
588	Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis. <i>Journal of Infectious Diseases</i> , 2020 , 221, 589-597	7	7
587	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1019-1040	3.2	27
586	High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy. <i>Journal of Infectious Diseases</i> , 2020 , 222, 1345-1352	7	2
585	Hepatitis C virus genotypes 1-3 infections regulate lipogenic signaling and suppress cholesterol biosynthesis in hepatocytes. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1382-1395	3.2	0
584	Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1871-1875	3.2	2
583	Hepatitis B: Immunization and Impact on Natural History and Cancer Incidence. <i>Gastroenterology Clinics of North America</i> , 2020 , 49, 201-214	4.4	7
582	Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1476-1482	3.2	4

581	Modelling NAFLD disease burden in four Asian regions-2019-2030. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 801-811	6.1	31
580	HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. <i>Journal of Hepatology</i> , 2020 , 72, 1105-1111	13.4	15
579	Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. <i>Clinical Microbiology Reviews</i> , 2020 , 33,	34	82
578	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis. <i>Scientific Reports</i> , 2020 , 10, 9180	4.9	2
577	The association of vitamin D with hepatitis B virus replication: Bystander rather than offender. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1634-1641	3.2	5
576	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 568-575	3.4	12
575	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. <i>Liver Cancer</i> , 2020 , 9, 207-220	9.1	7
574	The clinical manifestations and management of COVID-19-related liver injury. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1016-1018	3.2	23
573	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1135-1157	3.2	34
572	Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis. <i>Scientific Reports</i> , 2020 , 10, 5372	4.9	2
571	Hepatitis C and hepatitis B coinfection 2020 , 182-188		1
570	Withdrawal of Nucleos(t)ide Analogues in Hepatitis B e Antigen-Negative Patients: An Asian Perspective. <i>Clinical Liver Disease</i> , 2020 , 16, 244-248	2.2	0
569	Hepatitis B reactivation: diagnosis and management. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 565-578	4.2	9
568	Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 712-719	3.2	2
567	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. <i>Liver International</i> , 2020 , 40, 758-768	7.9	11
566	Hepatobiliary and Pancreatic: Biliary hamartoma manifests as liver cysts. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 11	4	
565	Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer. <i>International Journal of Cancer</i> , 2020 , 147, 901-908	7.5	4
564	Systematic review: chronic viral hepatitis and metabolic derangement. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 216-230	6.1	28

563	Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2840-2848	11.6	14
562	Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. <i>Journal of Hepatology</i> , 2020 , 72, 839-846	13.4	23
561	Letter: hepatitis B virus infection and risk of multiple myeloma-a meta-analysis of cohort studies. AuthorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 310-311	6.1	
560	Gender Difference in the Association Between Metabolic Factors and Hepatocellular Carcinoma. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa036	4.6	4
559	Towards elimination of viral hepatitis in Taiwan by 2025: In memory of Professor Ding-Shinn Chen (1943-2020). <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1247-1248	3.2	1
558	Relationship between serum gamma-glutamyl transferase level and colorectal adenoma. <i>PLoS ONE</i> , 2020 , 15, e0240445	3.7	0
557	Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1483-1489	3.2	3
556	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>American Journal of Gastroenterology</i> , 2020 , 115, 1226-1235	0.7	8
555	Reply to letter to the editor: Successful eradication of HCV by short-course DAAs in HCV positive donor to HCV-Negative recipient during Haplo-HSCT. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1719-1720	3.2	
554	Progress towards elimination goals for viral hepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 533-542	24.2	41
553	Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00196	4.2	4
552	East Asia expert opinion on treatment initiation for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1540-1550	6.1	6
551	Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH). <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa397	1	0
550	A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results. <i>Journal of Hepatology</i> , 2020 , 73, S67-S68	13.4	2
549	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. <i>Journal of Microbiology, Immunology and Infection</i> , 2020 , 53, 569-577	8.5	14
548	Improved quantitative assessment of HBV-associated liver fibrosis using second-harmonic generation microscopy with feature selection. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020 , 44, 12-20	2.4	2
547	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020 , 221, 389-399	7	22
546	Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction?. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 3-11	3.2	9

545	Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. <i>Molecular Therapy - Nucleic Acids</i> , 2020 , 20, 480-490	10.7	36
544	Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection-AuthorsN reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1764	6.1	
543	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. <i>Hepatology International</i> , 2019 , 13, 587-598	8.8	22
542	APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. <i>Hepatology International</i> , 2019 , 13, 649-661	8.8	36
541	High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. <i>Gastroenterology</i> , 2019 , 157, 1518-1529.e3	13.3	45
540	Nucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop?. <i>Gut</i> , 2019 , 68, 2105-2106	21.06	4
539	Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 1014-1023	3.2	7
538	Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 589-598	6.1	19
537	Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 1620-1625	4	12
536	The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogue Cessation Among Asian Chronic Hepatitis B Patients: Friend or Foe?. <i>Hepatology</i> , 2019 , 69, 1843	11.2	2
535	Letter: contraindicated drug-drug interactions before and after initiation of direct-acting anti-viral agents in chronic hepatitis C patients in Taiwan. AuthorsNreply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 115-116	6.1	
534	NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 2179-2186	4	1
533	Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data. <i>Antiviral Therapy</i> , 2019 , 24, 133-140	1.6	8
532	An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions. <i>Journal of Infectious Diseases</i> , 2019 , 220, 557-566	7	10
531	Clinical evaluation of IntelliPlex HCV genotyping kit for hepatitis C virus genotyping. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019 , 94, 344-348	2.9	1
530	Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1040-1049	3.4	1
529	Quantification of Hepatitis B Core Antibody Helps Predict Clinical Relapse After Cessation of Nucleos(t)ide Analogues in Chronic Hepatitis B Patients: More Needs to Be Done. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1000-1001	6.9	2
528	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 1977-1983	4	3

527	Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Hepatology</i> , 2019 , 70, 184-197	11.2	2
526	Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma. <i>Hepatology</i> , 2019 , 69, 209-221	11.2	38
525	Role of HBsAg Testing in the Management of Patients with Chronic HBV. <i>Current Hepatology Reports</i> , 2019 , 18, 331-341	1	5
524	Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 1187-1192	3.2	10
523	Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism. <i>Movement Disorders</i> , 2019 , 34, 1882-1890	7	7
522	Profile and value of FIB-4 in patients with dual chronic hepatitis C and B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 410-417	4	9
521	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 556-564	3.2	8
520	Taiwan consensus statement on the management of chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 7-38	3.2	25
519	Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 331-339	6.1	8
518	Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2019 , 156, 635-646.e9	13.3	86
517	Quantification of HBV core antibodies may help revisit infectious occult hepatitis B virus. <i>Gut</i> , 2019 , 68, 2095	19.2	4
516	Large and middle hepatitis B surface antigen: the lower the better?. <i>Gut</i> , 2019 , 68, 376-377	19.2	
515	Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2018 , 117, 588-597	3.2	16
514	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. <i>Hepatology</i> , 2018 , 68, 1298-1307	11.2	121
513	Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1690-1698	6.1	19
512	Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1480-1489	6.1	14
511	Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 1507-1510	4	8
510	Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2018 , 117, 915-921	3.2	16

509	HCC risk in patients with HBV-related cirrhosis receiving nucleos(t)ide analogues therapy: Is HCC prevented or delayed?. <i>Hepatology</i> , 2018 , 67, 1634-1635	11.2	8
508	Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. <i>Journal of Infectious Diseases</i> , 2018 , 217, 1193-1201	7	41
507	Review article: the prevention of hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 5-14	6.1	32
506	Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. <i>Radiology</i> , 2018 , 288, 293-299	20.5	8
505	A noninvasive diagnosis of hepatic fibrosis by BioFibroScore [®] in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 291-297	4	11
504	Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2018 , 117, 497-504	3.2	3
503	Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018 , 66, 289-292	11.6	22
502	Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , 2018 , 68, 415-424	11.2	32
501	Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use. <i>Journal of Hepatology</i> , 2018 , 68, S87	13.4	7
500	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1429-1437	3.4	14
499	Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma. <i>Liver International</i> , 2018 , 38, 2248-2259	7.9	4
498	Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. <i>Journal of Clinical Investigation</i> , 2018 , 128, 668-681	15.9	104
497	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , 2018 , 38, 1179-1187	7.9	16
496	Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 710-717	4	21
495	A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment 2018 , 6, 144		16
494	Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. <i>PLoS ONE</i> , 2018 , 13, e0209299	3.7	7
493	One-year weight management lowers lipopolysaccharide-binding protein and its implication in metainflammation and liver fibrosis. <i>PLoS ONE</i> , 2018 , 13, e0207882	3.7	3
492	Sarcopenia and chronic liver diseases. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 1229-1244	12.44	39

491	Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1290-1300	6.1	29
490	Hepatitis B: From control to cure. <i>Journal of the Formosan Medical Association</i> , 2018 , 117, 868-870	3.2	9
489	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. <i>Scientific Reports</i> , 2018 , 8, 13694	4.9	20
488	Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir. <i>Journal of the Formosan Medical Association</i> , 2017 , 116, 407-409	3.2	4
487	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 161-176	18.8	1196
486	Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 1512-1519	4.9	7
485	Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. <i>Liver International</i> , 2017 , 37, 310-311	7.9	0
484	More viral mutants, less HBsAg clearance? One size may not fit all. <i>Gut</i> , 2017 , 66, 1349	19.2	
483	Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study. <i>Hepatology</i> , 2017 , 66, 681	11.2	7
482	Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2017 , 31, 249-255	2.5	83
481	De novo assembly of highly polymorphic metagenomic data using in situ generated reference sequences and a novel BLAST-based assembly pipeline. <i>BMC Bioinformatics</i> , 2017 , 18, 223	3.6	12
480	An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017 , 11, 759-772	4.2	9
479	Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. <i>Scientific Reports</i> , 2017 , 7, 3718	4.9	13
478	HBV markers for HCC prediction: Three heads are better than two?. <i>Journal of Hepatology</i> , 2017 , 67, 203-204	13.4	5
477	Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 1998-2005	4	14
476	Elimination of Hepatitis B: Is It a Mission Possible?. <i>BMC Medicine</i> , 2017 , 15, 53	11.4	19
475	Urgency to treat patients with chronic hepatitis C in Asia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 966-974	4	18
474	Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up. <i>Journal of the Formosan Medical Association</i> , 2017 , 116, 697-704	3.2	13

473	High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments. <i>PLoS ONE</i> , 2017 , 12, e0170028	3.7	12
472	Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy. <i>BMC Gastroenterology</i> , 2017 , 17, 154	3	5
471	NOhep: Toward Global Control of Hepatitis B Virus Infection-An Introduction. <i>Journal of Infectious Diseases</i> , 2017 , 216, S749	7	3
470	Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1564-1574	0.7	31
469	Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 480-481	6.1	3
468	Strategies to manage hepatitis C virus infection disease burden-Volume 4. <i>Journal of Viral Hepatitis</i> , 2017 , 24 Suppl 2, 44-63	3.4	13
467	The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4. <i>Journal of Viral Hepatitis</i> , 2017 , 24 Suppl 2, 25-43	3.4	19
466	Historical epidemiology of hepatitis C virus in select countries-volume 4. <i>Journal of Viral Hepatitis</i> , 2017 , 24 Suppl 2, 8-24	3.4	26
465	Letter: the influence of direct acting agents for hepatitis C, on hepatitis B reactivation. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 208	6.1	
464	Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. <i>Scientific Reports</i> , 2017 , 7, 1728	4.9	6
463	MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1B infection. <i>Journal of Hepatology</i> , 2017 , 66, S90-S91	13.4	47
462	Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 73-81	4	4
461	Surveillance of Hepatocellular Carcinoma by Magnetic Resonance Imaging With Liver-Specific Contrast. <i>JAMA Oncology</i> , 2017 , 3, 446-447	13.4	3
460	Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B. <i>Current Medical Research and Opinion</i> , 2017 , 33, 495-504	2.5	12
459	Unmet Needs in Clinical and Basic Hepatitis B Virus Research. <i>Journal of Infectious Diseases</i> , 2017 , 216, S750-S756	7	16
458	Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection. <i>Open Forum Infectious Diseases</i> , 2017 , 4, ofx028	1	35
457	Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. <i>Oncotarget</i> , 2017 , 8, 65077-65089	3.3	12
456	Associated factors and clinical implications of serum aminotransferase elevation in scrub typhus. <i>Journal of Microbiology, Immunology and Infection</i> , 2016 , 49, 941-946	8.5	3

455	Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. <i>Hepatology International</i> , 2016 , 10, 294-301	8.8	2
454	Hepatitis C virus infection in Taiwan: Past, present, and future. <i>Journal of the Formosan Medical Association</i> , 2016 , 115, 65-6	3.2	55
453	Perspectives on dual hepatitis B and C infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2016 , 115, 298-305	3.2	10
452	No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1202-1204	11.6	45
451	Liver Gene Expression Profiles Correlate with Virus Infection and Response to Interferon Therapy in Chronic Hepatitis B Patients. <i>Scientific Reports</i> , 2016 , 6, 31349	4.9	18
450	Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. <i>Liver International</i> , 2016 , 36, 1755-1764	7.9	119
449	Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy. <i>Scientific Reports</i> , 2016 , 6, 32303	4.9	10
448	Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2016 , 115, 953-960	3.2	5
447	Review article: novel therapies for hepatitis B virus cure - advances and perspectives. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 213-22	6.1	39
446	Revisiting the Natural History of Chronic HBV Infection. <i>Current Hepatology Reports</i> , 2016 , 15, 141-149	1	11
445	Management of hepatitis C patients with decompensated liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 679-88	4.2	5
444	Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. <i>Hepatology International</i> , 2016 , 10, 258-66	8.8	7
443	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 461-468.e2	6.9	18
442	How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 911-9	4	9
441	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016 , 10, 1-98	8.8	1288
440	Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF-B signaling and tumor progression in a woodchuck hepatocellular carcinoma model. <i>Oncotarget</i> , 2016 , 7, 47173-47185	3.3	3
439	Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. <i>Annals of Hepatology</i> , 2016 , 15, 333-49	3.1	1
438	New perspectives of biomarkers for the management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2016 , 22, 423-431	6.9	41

437	Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection. <i>Medicine (United States)</i> , 2016 , 95, e2995	1.8	16
436	Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1757-1765	4.7	7
435	Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1323-9	4	21
434	Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study. <i>Hepatology</i> , 2016 , 63, 721-30	11.2	31
433	Reply. <i>Hepatology</i> , 2016 , 64, 1814	11.2	
432	Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. <i>Journal of Interferon and Cytokine Research</i> , 2016 , 36, 635-643	3.5	7
431	Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. <i>Liver International</i> , 2016 , 36, 954-62	7.9	13
430	Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues. <i>Hepatology Research</i> , 2016 , 46, 642-9	5.1	1
429	All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study. <i>Liver International</i> , 2016 , 36, 1433-41	7.9	24
428	Pegylated IFN- β suppresses hepatitis C virus by promoting the DAPK-mTOR pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 14799-14804	11.5	8
427	Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E-Antigen-Negative Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1490-1498.e3	6.9	34
426	APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. <i>Hepatology International</i> , 2016 , 10, 681-701	8.8	60
425	Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1286-94	0.7	49
424	APASL consensus statements and recommendation on treatment of hepatitis C. <i>Hepatology International</i> , 2016 , 10, 702-26	8.8	155
423	A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. <i>Liver International</i> , 2016 , 36, 1101-7	7.9	24
422	Hepatitis B virus: new therapeutic perspectives. <i>Liver International</i> , 2016 , 36 Suppl 1, 85-92	7.9	35
421	HIV/HCV Coinfection in Taiwan. <i>AIDS Reviews</i> , 2016 , 18, 193-197	1.5	2
420	Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection. <i>Hepatology International</i> , 2015 , 9, 35-42	8.8	11

419	Reimbursement policies in the Asia-Pacific for chronic hepatitis B. <i>Hepatology International</i> , 2015 , 9, 43-51	5.8	17
418	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 7243-8	11.5	49
417	A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. <i>Hepatology International</i> , 2015 , 9, 378-90	8.8	68
416	Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy. <i>Journal of Infectious Diseases</i> , 2015 , 211, 1429-36	7	7
415	Artificial ascites is feasible and effective for difficult-to-ablate hepatocellular carcinoma. <i>Hepatology International</i> , 2015 , 9, 514-9	8.8	19
414	Improving clinical outcomes of chronic hepatitis B virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 141-54	4.2	20
413	Comparison of Abbott RealTime HCV Genotype II with Versant line probe assay 2.0 for hepatitis C virus genotyping. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 1754-7	9.7	51
412	Hepatitis B virus genotypes and variants. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015 , 5, a021436	5.4	132
411	Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2015 , 9, 231-42	8.8	24
410	Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 949-60	6.1	41
409	Hepatitis B virus infection and metabolic syndrome: fact or fiction?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 14-20	4	57
408	Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients. <i>Journal of the Formosan Medical Association</i> , 2015 , 114, 923-8	3.2	16
407	Hepatitis B vaccination and prevention of hepatocellular carcinoma. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2015 , 29, 907-17	2.5	51
406	Perspectives and control of hepatitis B virus infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2015 , 114, 901-9	3.2	52
405	Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 197-203	9.5	73
404	Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 596-606	3.4	18
403	Treating Immune-tolerant Hepatitis B. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 77-84	3.4	30
402	HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients. <i>Journal of the Formosan Medical Association</i> , 2015 , 114, 308-13	3.2	8

401	Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. <i>Gut</i> , 2015 , 64, 292-302	19.2	82
400	Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir. <i>Journal of the Formosan Medical Association</i> , 2015 , 114, 1140-1	3.2	8
399	On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy. <i>Antiviral Therapy</i> , 2015 , 20, 369-75	1.6	46
398	Reply to: Modulation of Toll-like receptor 9 expression on monocytes of viral hepatitis patients. <i>Antiviral Therapy</i> , 2015 , 20, 669-70	1.6	
397	P0809 : 98% SVR12 in Korean And Taiwanese patients with chronic genotype 2 HCV infection receiving 12 weeks of sofosbuvir plus ribavirin: Results from an international, multicenter phase 3 study. <i>Journal of Hepatology</i> , 2015 , 62, S638	13.4	3
396	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. <i>Scientific Reports</i> , 2015 , 5, 11710	4.9	7
395	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. <i>Scientific Reports</i> , 2015 , 5, 15255	4.9	7
394	Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study. <i>Scientific Reports</i> , 2015 , 5, 17410	4.9	11
393	Micro-evolution of the hepatitis B virus genome in hepatitis B e-antigen-positive carriers: comparison of genotypes B and C at various immune stages. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 172-7	4	1
392	Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nation-wide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 902-11	6.1	26
391	Can noninvasive biomarkers replace liver biopsy for chronic hepatitis B?. <i>Hepatology</i> , 2015 , 62, 1924-5	11.2	1
390	Serum Biomarkers Predictive of Significant Fibrosis and Cirrhosis in Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2015 , 49, 705-13	3	30
389	Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2015 , 5, 9954	4.9	41
388	Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 9-20	4.2	6
387	Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan. <i>Journal of Hepatology</i> , 2015 , 63, 354-63	13.4	45
386	Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System. <i>Journal of Infectious Diseases</i> , 2015 , 211, 1566-73	7	13
385	Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure. <i>Gut</i> , 2015 , 64, 1314-26	19.2	198
384	What can we learn from hepatitis B virus clinical cohorts?. <i>Liver International</i> , 2015 , 35 Suppl 1, 91-9	7.9	10

383	Viral hepatitis. HBV cure--can we pin our hopes on immunotherapy?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015 , 12, 129-31	24.2	23
382	New insights into the evolutionary rate of hepatitis B virus at different biological scales. <i>Journal of Virology</i> , 2015 , 89, 3512-22	6.6	28
381	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naïve patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. <i>Gut</i> , 2015 , 64, 303-11	19.2	32
380	Detectability and clinical significance of serum hepatitis B virus ribonucleic acid. <i>Hepatobiliary Surgery and Nutrition</i> , 2015 , 4, 197-202	2.1	5
379	Factors affecting the diagnostic accuracy of ultrasonography in assessing the severity of hepatic steatosis. <i>Journal of the Formosan Medical Association</i> , 2014 , 113, 249-54	3.2	8
378	Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 1242-9	4	14
377	A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. <i>Journal of the Formosan Medical Association</i> , 2014 , 113, 716-21	3.2	8
376	All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. <i>Lancet, The</i> , 2014 , 384, 1597-605	40	278
375	Hepatic necro-inflammation and elevated liver enzymes: evaluation with MRI perfusion imaging with gadoxetic acid in chronic hepatitis patients. <i>Clinical Radiology</i> , 2014 , 69, 473-80	2.9	9
374	Vascular and hepatic enhancements at MR imaging: comparison of Gd-EOB-DTPA and Gd-DTPA in the same subjects. <i>Clinical Imaging</i> , 2014 , 38, 287-91	2.7	3
373	P1118 NO EFFECT OF FALDAPREVIR ON RENAL FUNCTION IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: POOLED DATA FROM TWO PHASE III TRIALS. <i>Journal of Hepatology</i> , 2014 , 60, S451	13.4	3
372	O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS. <i>Journal of Hepatology</i> , 2014 , 60, S524-S525	13.4	18
371	P1300 EFFICACY AND SAFETY OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DCV+ASV) IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1B: RESULTS OF THE HALLMARK DUAL STUDY. <i>Journal of Hepatology</i> , 2014 , 60, S527-S528	13.4	6
370	Peginterferon in the treatment of chronic hepatitis B. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 995-1006	5.4	13
369	Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: a prospective study in taiwan. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 1659-71	20	
368	Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients. <i>Journal of the Formosan Medical Association</i> , 2014 , 113, 786-93	3.2	7
367	Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. <i>International Journal of Nanomedicine</i> , 2014 , 9, 2051-67	7.3	16
366	Reduced toll-like receptor 9 expression on peripheral CD14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy. <i>Antiviral Therapy</i> , 2014 , 19, 637-43	1.6	16

365	Triple therapy for hepatitis C virus infection in patients receiving hemodialysis. <i>Annals of Internal Medicine</i> , 2014 , 160, 581-2	8	1
364	Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 102-9	4	6
363	Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. <i>Emerging Microbes and Infections</i> , 2014 , 3, e64	18.9	84
362	The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. <i>Molecular Therapy - Nucleic Acids</i> , 2014 , 3, e186	10.7	274
361	Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 10578-604	6.3	48
360	Younger age and female sex predict a better therapeutic response in HBeAg-positive chronic hepatitis B patients to entecavir therapy. <i>Advances in Digestive Medicine</i> , 2014 , 1, 112-117	0.1	0
359	Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study. <i>Hepatology</i> , 2014 , 60, 807-14	11.2	78
358	HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?. <i>Liver International</i> , 2014 , 34 Suppl 1, 112-9	7.9	37
357	Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously. <i>Liver International</i> , 2014 , 34, e71-9	7.9	11
356	Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: clinical and mechanistic implications. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 1629-36	4	21
355	Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 185-92	4	8
354	O113 COMBINATION THERAPY WITH PEGINTERFERON ALFA-2a AND A NUCLEOS(T)IDE ANALOGUE FOR HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS: RESULTS OF A LARGE, RANDOMISED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. <i>Journal of Hepatology</i> , 2014 , 60, 847	13.4	7
353	Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. <i>Journal of Gastroenterology</i> , 2014 , 49, 356-62	6.9	13
352	Risk stratification of HBV infection in Asia-Pacific region. <i>Clinical and Molecular Hepatology</i> , 2014 , 20, 223-7	6.9	16
351	Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. <i>Hepatology International</i> , 2013 , 7, 171-9	8.8	5
350	Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. <i>Hepatology International</i> , 2013 , 7, 316-26	8.8	40
349	IL28B Genotype on HCV Infection in Asia. <i>Current Hepatitis Reports</i> , 2013 , 12, 149-156		2
348	Hepatitis B Virus Genotypes: Clinical Relevance and Therapeutic Implications. <i>Current Hepatitis Reports</i> , 2013 , 12, 124-132		

347	Evolution of viral biomarkers in predicting outcomes of chronic hepatitis B patients: From DNA to surface antigen. <i>Tzu Chi Medical Journal</i> , 2013 , 25, 75-81	1.1	2
346	Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. <i>Seminars in Liver Disease</i> , 2013 , 33, 97-102	7.3	122
345	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. <i>Hepatology</i> , 2013 , 57, 2135-42	11.2	55
344	Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. <i>Journal of Clinical Virology</i> , 2013 , 56, 293-8	14.5	19
343	Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. <i>Journal of Gastroenterology</i> , 2013 , 48, 13-21	6.9	84
342	Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 46-50	4	22
341	758 ENTECAVIR PLUS PEGINTERFERON alfa-2a vs. ENTECAVIR ALONE IN THE TREATMENT OF HEPATITIS B e ANTIGEN-POSITIVE CHRONIC HEPATITIS B: AN INTERIM REPORT. <i>Journal of Hepatology</i> , 2013 , 58, S308	13.4	3
340	1421 ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS). <i>Journal of Hepatology</i> , 2013 , 58, S572	13.4	3
339	Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers. <i>Journal of Infectious Diseases</i> , 2013 , 208, 584-93	7	37
338	Milder clinical manifestation of scrub typhus in Kinmen, Taiwan. <i>Journal of the Formosan Medical Association</i> , 2013 , 112, 201-7	3.2	18
337	Risk stratification for hepatitis B virus related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 10-7	4	71
336	Hepatitis B viral factors and treatment responses in chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2013 , 112, 302-11	3.2	32
335	Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. <i>Hepatology</i> , 2013 , 57, 934-43	11.2	45
334	Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study. <i>Clinical Infectious Diseases</i> , 2013 , 57, 1695-702	11.6	67
333	Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. <i>Gut</i> , 2013 , 62, 182-4	19.2	58
332	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2332-8	5.1	16
331	Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 415-23	6.1	91
330	Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 7844-9	11.5	55

329	Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. <i>Hepatology</i> , 2013 , 57, 441-50	11.2	183
328	IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients. <i>Antiviral Therapy</i> , 2013 , 18, 599-606	1.6	9
327	Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy. <i>Antiviral Therapy</i> , 2013 , 18, 877-84	1.6	35
326	Pegylated interferon- α with or without low-dose ribavirin for treatment-naïve patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. <i>Annals of Internal Medicine</i> , 2013 , 159, 729-38	8	79
325	Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. <i>PLoS ONE</i> , 2013 , 8, e53008	3.7	39
324	Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection. <i>PLoS ONE</i> , 2013 , 8, e55916	3.7	16
323	Biphasic pattern of depression and its predictors during pegylated interferon-based therapy in chronic hepatitis B and C patients. <i>Antiviral Therapy</i> , 2013 , 18, 567-73	1.6	8
322	Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients. <i>PLoS ONE</i> , 2013 , 8, e70458	3.7	28
321	Treatment options for dual HCV/HBV coinfection 2013 , 72-84		
320	Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. <i>Hepatology</i> , 2012 , 55, 68-76	11.2	104
319	Hepatitis B virus mutants associated with hepatitis B surface antigen loss: chicken or egg?. <i>Hepatology</i> , 2012 , 55, 656-7	11.2	
318	1406 ALISPORIVIR (ALV) PLUS PEG-INTERFERON/RIBAVIRIN (PR) IN HCV G1 TREATMENT-EXPERIENCED PATIENTS ACHIEVES PRIMARY ENDPOINT WITH SUPERIOR EFFICACY AT TREATMENT WEEK 12 COMPARED TO RETREATMENT WITH PR. <i>Journal of Hepatology</i> , 2012 , 56, S553-S554	13.4	8
317	Fine mapping of hepatitis B virus pre-S deletion and its association with hepatocellular carcinoma. <i>Liver International</i> , 2012 , 32, 1373-81	7.9	29
316	High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. <i>Gastroenterology</i> , 2012 , 142, 1140-1149.e3; quiz e13-4	13.3	362
315	Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2012 , 111, 527-35	3.2	24
314	Severity of fatty liver on ultrasound correlates with metabolic and cardiovascular risk. <i>Kaohsiung Journal of Medical Sciences</i> , 2012 , 28, 151-60	2.4	13
313	Persistent hepatitis B viral replication in a FVB/N mouse model: impact of host and viral factors. <i>PLoS ONE</i> , 2012 , 7, e36984	3.7	24
312	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. <i>Hepatology International</i> , 2012 , 6, 531-61	8.8	768

311	Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission. <i>Hepatology International</i> , 2012 , 6, 598-605	8.8	1
310	Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. <i>Hepatology International</i> , 2012 , 6, 591-7	8.8	15
309	APASL consensus statements and management algorithms for hepatitis C virus infection. <i>Hepatology International</i> , 2012 , 6, 409-35	8.8	139
308	Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. <i>European Radiology</i> , 2012 , 22, 171-80	8	86
307	Impact of hepatitis B virus infection on metabolic profiles and modifying factors. <i>Journal of Viral Hepatitis</i> , 2012 , 19, e48-57	3.4	48
306	Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2012 , 17, 477-84	4.6	38
305	Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. <i>Journal of Infectious Diseases</i> , 2012 , 206, 1521-31	7	41
304	Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2012 , 54, 548-55	11.6	12
303	Association of hepatitis C virus infection and malnutrition-inflammation complex syndrome in maintenance hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27, 1176-83	4.3	8
302	Genomic variation-guided management in chronic hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012 , 6, 497-506	4.2	8
301	Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. <i>Journal of Infectious Diseases</i> , 2012 , 205, 54-63	7	41
300	Clinical and histologic implications of delayed hepatobiliary enhancement on magnetic resonance imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic Acid. <i>Investigative Radiology</i> , 2012 , 47, 649-55	10.1	17
299	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. <i>Antiviral Therapy</i> , 2012 , 17, 1059-67	1.6	21
298	Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. <i>PLoS ONE</i> , 2012 , 7, e52048	3.7	22
297	Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. <i>Gastroenterology</i> , 2011 , 141, 517-25, 525.e1-2	13.3	154
296	IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations. <i>Journal of General Virology</i> , 2011 , 92, 1071-1081	4.9	46
295	Alpha-fetoprotein in chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2011 , 110, 730	3.2	
294	Uncovered issues in the overview of nonalcoholic steatohepatitis. <i>Journal of the Formosan Medical Association</i> , 2011 , 110, 798	3.2	

293	Hepatitis during antituberculosis treatment. <i>Journal of the Formosan Medical Association</i> , 2011 , 110, 801	3.2	
292	Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. <i>Journal of Hepatology</i> , 2011 , 55, 1121-31	13.4	237
291	Boceprevir for chronic HCV genotype 1 infection. <i>New England Journal of Medicine</i> , 2011 , 365, 176-7; author reply 177-8	59.2	18
290	HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection. <i>Antiviral Therapy</i> , 2011 , 16, 227-35	1.6	5
289	Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon- α therapy. <i>Antiviral Therapy</i> , 2011 , 16, 629-37	1.6	71
288	Treatment of hepatitis C virus infection in patients with end-stage renal disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26, 228-39	4	64
287	The clinical implications of hepatitis B virus genotype: Recent advances. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26 Suppl 1, 123-30	4	271
286	The clinical significance of occult hepatitis B transfusion in Taiwan--a look-back study. <i>Transfusion Medicine</i> , 2011 , 21, 33-41	1.3	29
285	Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: genotype B vs C. <i>Journal of Viral Hepatitis</i> , 2011 , 18, e482-90	3.4	21
284	Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. <i>Hepatology International</i> , 2011 , 5, 814-21	8.8	12
283	HBV/A and HBV/C genotype predominance among patients with chronic hepatitis B virus infection in Cebu City, Philippines. <i>Hepatology International</i> , 2011 , 5, 774-81	8.8	5
282	Hepatitis C virus and lipid profiles: more questions than answers?. <i>Hepatology International</i> , 2011 , 5, 865-8	8.8	2
281	Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy. <i>Journal of Medical Virology</i> , 2011 , 83, 1212-20	19.7	10
280	Aboriginal Taiwanese hepatitis B carriers have more favorable viral factors than Han Chinese carriers. <i>Journal of Medical Virology</i> , 2011 , 83, 1326-31	19.7	3
279	Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. <i>Hepatology</i> , 2011 , 53, 429-36	11.2	54
278	Pathogenesis and management of alcoholic liver cirrhosis: a review. <i>Hepatic Medicine: Evidence and Research</i> , 2011 , 3, 1-11	3.4	6
277	Recent advances in the treatment of chronic hepatitis B. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2025-40	4	23
276	Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. <i>Journal of Infection</i> , 2011 , 62, 448-55	18.9	57

275	Reply to Guedj et al.: Early transient increase of hepatitis C virus viral load in genotype 1 and 2 infections, and the use of mathematical modeling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, E303-E303	11.5	78
274	Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 1057-65	6.9	64
273	Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 3719-24	11.5	54
272	Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. <i>PLoS ONE</i> , 2011 , 6, e20752	3.7	17
271	Molecular epidemiology of hepatitis B virus. <i>Korean Journal of Internal Medicine</i> , 2011 , 26, 255-61	2.5	45
270	Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. <i>Genes and Immunity</i> , 2010 , 11, 87-93	4.4	29
269	Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010 , 25, 970-7	4	27
268	Asymptomatic chronic hepatitis B virus infection does not increase the risk of diabetes mellitus: a ten-year observation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010 , 25, 1420-5	4	37
267	Outcomes of HCV treatment: who does well and who does not?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010 , 25, 846-8	4	1
266	Optimal management of hepatocellular carcinoma: challenges and opportunities. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010 , 25, 1336-8	4	9
265	Rifaximin treatment in hepatic encephalopathy. <i>New England Journal of Medicine</i> , 2010 , 362, 2423; author reply 2424-5	59.2	9
264	Metabolic syndrome on top of chronic hepatitis B: the more, the worse?. <i>Gut</i> , 2010 , 59, 276-7; author reply 277	19.2	1
263	Use of statins and gallstone risk. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 303, 1146; author reply 1147	27.4	2
262	Intrathecal delivery of a mutant micro-opioid receptor activated by naloxone as a possible antinociceptive paradigm. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010 , 334, 739-45	4.7	19
261	Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. <i>Clinical Infectious Diseases</i> , 2010 , 51, 541-9	11.6	26
260	HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. <i>Journal of Infectious Diseases</i> , 2010 , 202, 86-92	7	42
259	Alanine aminotransferase, metabolic syndrome, and cardiovascular disease: a missing link?. <i>American Journal of Gastroenterology</i> , 2010 , 105, 224; author reply 224-5	0.7	1
258	A novel antibody associated with autoimmune pancreatitis. <i>New England Journal of Medicine</i> , 2010 , 362, 759; author reply 760-1	59.2	1

257	The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. <i>Kidney International</i> , 2010 , 78, 103-9	9.9	27
256	Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects. <i>Advances in Cancer Research</i> , 2010 , 108, 21-72	5.9	68
255	Role of viral factors in modifying weight-related effects on disease progression of chronic hepatitis C patients. <i>Gastroenterology</i> , 2010 , 138, 788-9; author reply 789	13.3	2
254	Clinical implications of hepatitis B virus variants. <i>Journal of the Formosan Medical Association</i> , 2010 , 109, 321-5	3.2	7
253	Implications of Hepatitis B Virus Genomic Variations on Treatment Outcomes. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2010 , 8, 280-288	0.4	4
252	Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010 , 15, 1133-9	1.6	72
251	Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010 , 15, 177-84	1.6	38
250	Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. <i>Antiviral Therapy</i> , 2010 , 15, 145-55	1.6	37
249	Treatment of chronic hepatitis B in Asia-Pacific countries: is the Asia-Pacific consensus statement being followed?. <i>Antiviral Therapy</i> , 2010 , 15, 607-16	1.6	9
248	A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection. <i>Hepatology International</i> , 2010 , 4, 516-22	8.8	14
247	Increased incidence of gastroesophageal reflux disease in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2010 , 4, 585-93	8.8	13
246	Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 2727-34	4	73
245	Carvedilol versus variceal band ligation for prevention of the first variceal bleed. <i>Hepatology</i> , 2010 , 51, 718-9	11.2	
244	Hepatitis C virus infection, lipids, and coronary heart disease: a Pandora's box. <i>Hepatology</i> , 2010 , 51, 343; author reply 343-4	11.2	4
243	From liver markers to life expectancy. <i>Hepatology</i> , 2010 , 51, 720; author reply 720-1	11.2	
242	Metformin improves sustained virologic response in difficult-to-cure hepatitis C: more questions than answers. <i>Hepatology</i> , 2010 , 51, 1082; author reply 1082-3	11.2	1
241	Esomeprazole for asthma. <i>New England Journal of Medicine</i> , 2009 , 361, 206; author reply 207-8	59.2	1
240	Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. <i>Gut</i> , 2009 , 58, 314-6	19.2	22

239	Peginterferon alfa-2b or alfa-2a with ribavirin for hepatitis C. <i>New England Journal of Medicine</i> , 2009 , 361, 1808-9; author reply 1809	59.2	3
238	Both insulin resistance and alanine aminotransferase level increase the risks of cardiovascular disease in fatty liver disease. <i>Hepatology</i> , 2009 , 50, 989; author reply 989-90	11.2	
237	Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus. <i>Journal of Medical Virology</i> , 2009 , 81, 588-93	19.7	6
236	Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis. <i>Digestive Diseases and Sciences</i> , 2009 , 54, 1337-46	4	27
235	High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2009 , 3, 364-70	8.8	30
234	Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism is associated with choledocholithiasis in Taiwanese patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 1559-61	4	1
233	Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 1411-6	4	38
232	Prevention of hepatocellular carcinoma in hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 1352-7	4	54
231	Reactivation of hepatitis B virus in an inactive hepatitis B carrier with glucocorticoid pulse therapy. <i>Digestive and Liver Disease</i> , 2009 , 41, 322-3	3.3	1
230	IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. <i>Digestive and Liver Disease</i> , 2009 , 41, 424-30	3.3	31
229	Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. <i>American Journal of Gastroenterology</i> , 2009 , 104, 598-604	0.7	32
228	Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. <i>Gastroenterology</i> , 2009 , 136, 496-504.e3	13.3	183
227	HBsAg seroclearance: the more and earlier, the better. <i>Gastroenterology</i> , 2009 , 136, 1842-3; author reply 1843-4	13.3	4
226	Hepatitis B virus basal core promoter mutation and DNA load correlate with expression of hepatitis B core antigen in patients with chronic hepatitis B. <i>Journal of Infectious Diseases</i> , 2009 , 199, 742-9	7	25
225	Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. <i>Antiviral Therapy</i> , 2009 , 14, 1157-63	1.6	24
224	Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. <i>American Journal of Gastroenterology</i> , 2009 , 104, 598-604	0.7	3
223	The Impact of p53 Mutations on the Course of Hepatitis B or C-related Chronic Liver Diseases in Taiwan. <i>American Journal of Gastroenterology</i> , 2009 , 104, S148	0.7	
222	Lower Alanine Aminotransferase Level and Higher Hepatitis B Viral Load at Baseline Correlate with Earlier Emergence of Lamivudine Resistance in Taiwanese Patients. <i>American Journal of Gastroenterology</i> , 2009 , 104, S119	0.7	

221	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2009 , 14, 45-54	1.6	10
220	Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. <i>Antiviral Therapy</i> , 2009 , 14, 203-10	1.6	2
219	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2009 , 14, 45-54	1.6	25
218	Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. <i>Antiviral Therapy</i> , 2009 , 14, 203-210	1.6	10
217	A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. <i>Liver International</i> , 2008 , 28, 1034-41	7.9	16
216	Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008 , 23, 779-82	4	72
215	Core promoter mutations of hepatitis B virus and hepatocellular carcinoma: story beyond A1762T/G1764A mutations. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008 , 23, 347-50	4	4
214	Association of Insulin Resistance with Alanine Aminotransferase Activity in Patients with Nonalcoholic Fatty Liver Disease. <i>Tzu Chi Medical Journal</i> , 2008 , 20, 275-279	1.1	4
213	Combination of hepatitis B viral factors and advanced liver disease in HBeAg-negative patients: the more, the worse?. <i>Gastroenterology</i> , 2008 , 134, 1270-1; author reply 1271	13.3	
212	HBV genotype and clinical outcome of chronic hepatitis B: facts and puzzles. <i>Gastroenterology</i> , 2008 , 134, 1272-3; author reply 1273	13.3	15
211	The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism. <i>Journal of Hepatology</i> , 2008 , 49, 899-907	13.4	18
210	Universal hepatitis B vaccination: killing 2 birds with 1 stone. <i>American Journal of Medicine</i> , 2008 , 121, 1029-31	2.4	10
209	Disease progression in a patient with nonalcoholic steatohepatitis. <i>Journal of the Formosan Medical Association</i> , 2008 , 107, 816-21	3.2	6
208	Diagnosis of hepatitis B virus infection through serological and virological markers. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008 , 2, 553-62	4.2	90
207	Pegylated interferon-alpha-2a plus ribavirin for treatment-naïve Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1260-9	11.6	165
206	Acute fatty liver of pregnancy with concurrent acute hepatitis B virus infection. <i>American Journal of Gastroenterology</i> , 2008 , 103, 2663-5	0.7	
205	Esophageal varices: noninvasive diagnosis with duplex Doppler US in patients with compensated cirrhosis. <i>Radiology</i> , 2008 , 248, 132-9	20.5	25
204	High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. <i>Liver International</i> , 2008 , 28, 271-7	7.9	77

203	Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. <i>Journal of Biomedical Science</i> , 2008 , 15, 137-45	13.3	82
202	Critical analysis of the immune tolerance phase of chronic HBV infection: Natural history and diagnosis. <i>Current Hepatitis Reports</i> , 2008 , 7, 5-11		3
201	Metabolic profiles in patients with chronic hepatitis C: a case-control study. <i>Hepatology International</i> , 2008 , 2, 250-7	8.8	27
200	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. <i>Hepatology International</i> , 2008 , 2, 263-83	8.8	761
199	Insulin resistance, adipocytokines, and hepatitis C virus infection: a missing link?. <i>Hepatology</i> , 2008 , 47, 760-1; author reply 761	11.2	
198	Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naïve dialysis patients with chronic hepatitis C: a randomised study. <i>Gut</i> , 2008 , 57, 525-30	19.2	51
197	Genetic variability of hepatitis B virus and response to antiviral therapy. <i>Antiviral Therapy</i> , 2008 , 13, 613-24	2.6	11
196	Genetic Variability of Hepatitis B virus and Response to Antiviral Therapy. <i>Antiviral Therapy</i> , 2008 , 13, 613-624	1.6	23
195	Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. <i>Gastroenterology</i> , 2007 , 132, 1287-93	13.3	272
194	Noninvasive diagnosis of hepatic fibrosis in patients with chronic hepatitis C by splenic Doppler impedance index. <i>Clinical Gastroenterology and Hepatology</i> , 2007 , 5, 1199-1206.e1	6.9	24
193	Viremia profiles in hepatitis B virus carrier children with spontaneous e antigen seroconversion: a case of dJlvu?. <i>Gastroenterology</i> , 2007 , 133, 1052-3; author reply 1053-4	13.3	
192	APRI-M6 for predicting long-term outcome of chronic hepatitis C patients after interferon-based therapy: more questions than answers. <i>Hepatology</i> , 2007 , 45, 1586-7; author reply 1587-8	11.2	
191	Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. <i>Hepatology</i> , 2007 , 45, 1193-8	11.2	93
190	Reply:. <i>Hepatology</i> , 2007 , 46, 947-949	11.2	3
189	High prevalence of occult hepatitis B virus infection in Taiwanese intravenous drug users. <i>Journal of Medical Virology</i> , 2007 , 79, 1674-8	19.7	23
188	Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 1098-103	4	72
187	Intrafamilial transmission of hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 765-6	4	3
186	Interferon-based therapy for dialysis patients with chronic hepatitis C: progress and challenges. <i>Nephrology</i> , 2007 , 12, 8-10	2.2	5

185	Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007 , 14, 64-9	3.4	19
184	Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007 , 14, 153-60	3.4	16
183	Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients. <i>Liver International</i> , 2007 , 27, 235-9	7.9	5
182	Subgenotypes of hepatitis B virus genotype C do not correlate with disease progression of chronic hepatitis B in Taiwan. <i>Liver International</i> , 2007 , 27, 983-8	7.9	13
181	Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. <i>Liver International</i> , 2007 , 27, 1356-63	7.9	73
180	Hepatitis B virus genotype: What should the clinician know?. <i>Current Hepatitis Reports</i> , 2007 , 6, 17-23		5
179	Role of viral factors in the natural course and therapy of chronic hepatitis B. <i>Hepatology International</i> , 2007 , 1, 415-30	8.8	78
178	Sequential combination therapy for chronic hepatitis B: more challenges to be tackled. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1544; author reply 1545	0.7	
177	Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. <i>Clinical Infectious Diseases</i> , 2007 , 44, 988-95	11.6	64
176	Hypercholesterolemia in primary biliary cirrhosis. <i>New England Journal of Medicine</i> , 2007 , 357, 1561-2	59.2	20
175	The effects of metabolic syndrome versus infectious burden on inflammation, severity of coronary atherosclerosis, and major adverse cardiovascular events. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 2532-7	5.6	17
174	Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2007 , 45, 1221-9	11.6	70
173	To genotype or not to genotype: toward an optimal tailoring of treatment of chronic hepatitis B. <i>Clinical Infectious Diseases</i> , 2007 , 44, 1665-6	11.6	3
172	Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2007 , 44, 584-90	11.6	9
171	Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. <i>Intervirology</i> , 2007 , 50, 310-5	2.5	16
170	Hepatitis B viral load as a prognostic factor for patients with unresectable hepatocellular carcinoma. <i>Future Virology</i> , 2007 , 2, 441-443	2.4	
169	Appropriate use of interferon for treatment of chronic hepatitis B. <i>Hepatology Research</i> , 2007 , 37, S47-54	1	19
168	Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. <i>Journal of the Chinese Medical Association</i> , 2007 , 70, 141-5	2.8	55

167	Concerns regarding thrombophilia testing. <i>Current Hepatitis Reports</i> , 2006 , 5, 5-6		27
166	Local ablation vs. resection for the treatment of hepatocellular carcinoma. <i>Hepatology</i> , 2006 , 43, 373	11.2	29
165	Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. <i>Hepatology</i> , 2006 , 43, 742-9	11.2	38
164	Mixed hepatitis B virus genotype infections: the more, the worse?. <i>Hepatology</i> , 2006 , 44, 770	11.2	7
163	Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. <i>Journal of Infectious Diseases</i> , 2006 , 194, 594-9	7	118
162	Clinical significance of occult hepatitis B virus infection cannot be overlooked. <i>Clinical Infectious Diseases</i> , 2006 , 42, 583-4	11.6	2
161	Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. <i>Journal of Infectious Diseases</i> , 2006 , 193, 1258-65	7	149
160	Evolution of Hepatitis B virus in an acute hepatitis B patient co-infected with genotypes B and C. <i>Journal of General Virology</i> , 2006 , 87, 39-49	4.9	27
159	Selective transmission of hepatitis C virus quasi species through a needlestick accident in acute resolving hepatitis. <i>Clinical Infectious Diseases</i> , 2006 , 42, 1254-9	11.6	10
158	High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. <i>Gastroenterology</i> , 2006 , 130, 1153-68	13.3	236
157	Kinetics of hepatitis B virus reactivation after chemotherapy: more questions than answers. <i>Gastroenterology</i> , 2006 , 131, 1656; author reply 1656-7	13.3	8
156	Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series. <i>Clinical Therapeutics</i> , 2006 , 28, 1327-34	3.5	6
155	Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. <i>Journal of Hepatology</i> , 2006 , 44, 39-46	13.4	93
154	Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2006 , 12, 6620-6	5.6	61
153	Pegylated interferons for the treatment of chronic hepatitis B. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2006 , 1, 85-94	1.6	4
152	Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: Correlation with viral characteristics. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006 , 21, 605-9	4	48
151	Higher cut-off index value of immunoglobulin M antibody to hepatitis B core antigen in Taiwanese patients with hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006 , 21, 859-62	4	14
150	Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006 , 21, 1789-93	4	16

149	Viral factors correlate with hepatitis B e antigen seroconversion in patients with chronic hepatitis B. <i>Liver International</i> , 2006 , 26, 949-55	7.9	38
148	Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. <i>Liver International</i> , 2006 , 26, 1087-94	7.9	49
147	Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 387-95	3.4	13
146	Hepatitis B vaccination: to boost or not to boost?. <i>Lancet, The</i> , 2005 , 366, 1337-8	4.0	36
145	Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005 , 43, 235-42	13.4	59
144	Effects of diabetes on the ED presentation of acute intermittent porphyria. <i>American Journal of Emergency Medicine</i> , 2005 , 23, 571-2	2.9	
143	Influence of hepatitis C virus infection on soluble cellular adhesion molecules in hemodialysis patients. <i>Blood Purification</i> , 2005 , 23, 106-12	3.1	12
142	Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. <i>Annals of Surgery</i> , 2005 , 242, 36-42	7.8	151
141	Typhoid fever and typhoid hepatitis in Taiwan. <i>Epidemiology and Infection</i> , 2005 , 133, 1073-9	4.3	10
140	Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. <i>Liver International</i> , 2005 , 25, 564-70	7.9	63
139	Prevalence and clinical implications of HFE gene mutations (C282Y and H63D) in patients with chronic hepatitis B and C in Taiwan. <i>Liver International</i> , 2005 , 25, 214-9	7.9	19
138	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. <i>Liver International</i> , 2005 , 25, 472-89	7.9	261
137	Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. <i>Liver International</i> , 2005 , 25, 696-703	7.9	87
136	Therapeutic implications of hepatitis B virus genotypes. <i>Liver International</i> , 2005 , 25, 1097-107	7.9	86
135	Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. <i>Liver International</i> , 2005 , 25, 752-9	7.9	28
134	HBV genotypes and outcome of HBV infection. <i>Hepatology</i> , 2005 , 41, 216; author reply 216	11.2	6
133	Application of hepatitis B virus genotyping and phylogenetic analysis in intrafamilial transmission of hepatitis B virus. <i>Clinical Infectious Diseases</i> , 2005 , 41, 1576-81	11.6	36
132	Subgenotypes of hepatitis B virus genotype C in Taiwan. <i>Journal of Infectious Diseases</i> , 2005 , 192, 1308-9; author reply 1309	7	6

131	Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 265-72	9.7	459
130	Medical treatment of fish bone-related liver abscess. <i>Clinical Infectious Diseases</i> , 2005 , 41, 1689-90	11.6	15
129	Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. <i>Antiviral Therapy</i> , 2005 , 10, 405-15	1.6	6
128	Influence of Metabolic Syndrome, Viral Genotype and Antiviral Therapy on Superimposed Fatty Liver Disease in Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2005 , 10, 405-415	1.6	20
127	Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy. <i>Liver International</i> , 2004 , 24, 9-15	7.9	14
126	Origin of serum hepatitis B virus in acute exacerbation: comparison with HBV in the liver and from other exacerbation. <i>Hepatology</i> , 2004 , 40, 310-17	11.2	18
125	Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. <i>Journal of Medical Virology</i> , 2004 , 72, 363-9	19.7	146
124	Precore/core promoter mutations and genotypes of hepatitis B virus in chronic hepatitis B patients with fulminant or subfulminant hepatitis. <i>Journal of Medical Virology</i> , 2004 , 72, 545-50	19.7	39
123	Genotypic dominance and novel recombinations in HBV genotype B and C co-infected intravenous drug users. <i>Journal of Medical Virology</i> , 2004 , 73, 13-22	19.7	41
122	Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion. <i>Journal of Medical Virology</i> , 2004 , 74, 237-45	19.7	22
121	High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users. <i>Journal of Medical Virology</i> , 2004 , 74, 536-42	19.7	35
120	Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2004 , 2, 64-71	6.9	46
119	Hepatitis B virus genotypes and core promoter variant. <i>Gastroenterology</i> , 2004 , 126, 633; author reply 633	13.3	1
118	Heterogeneity of hereditary persistence of alpha-fetoprotein. <i>Gastroenterology</i> , 2004 , 127, 687; author reply 688	13.3	2
117	Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. <i>Gastroenterology</i> , 2004 , 127, 1733-8	13.3	173
116	Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. <i>Journal of Hepatology</i> , 2004 , 41, 659-66	13.4	188
115	End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2004 , 10, 3574-8	5.6	13
114	Lack of interferon sensitivity-determining region in the genome of hepatitis B virus genotype Ba. <i>Antiviral Therapy</i> , 2004 , 9, 895-903	1.6	3

113	Lack of Interferon Sensitivity-Determining Region in the Genome of Hepatitis B Virus Genotype Ba. <i>Antiviral Therapy</i> , 2004 , 9, 895-903	1.6	9
112	Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. <i>Hepatology</i> , 2003 , 37, 568-76	11.2	94
111	Molecular assays for hepatitis B virus infection. <i>Hepatology</i> , 2003 , 38, 1311	11.2	6
110	TT virus infection in healthy children, children after blood transfusion, and children with non-A to E hepatitis or other liver diseases in Taiwan. <i>Journal of Medical Virology</i> , 2003 , 69, 66-71	19.7	23
109	Secular trend of age-specific prevalence of hepatitis B surface and e antigenemia in pregnant women in Taiwan. <i>Journal of Medical Virology</i> , 2003 , 69, 466-70	19.7	41
108	Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis-C virus infection in Taiwan: a prospective study. <i>Liver International</i> , 2003 , 23, 148-55	7.9	15
107	Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. <i>Liver International</i> , 2003 , 23, 426-33	7.9	17
106	A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. <i>Gastroenterology</i> , 2003 , 124, 80-90	13.3	60
105	Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. <i>Gastroenterology</i> , 2003 , 124, 327-34	13.3	464
104	Clinical relevance of hepatitis B virus genotypes Ba and Bj in Taiwan. <i>Gastroenterology</i> , 2003 , 125, 1916-7; author reply 1917-8	13.3	17
103	Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. <i>Intervirology</i> , 2003 , 46, 400-7	2.5	113
102	Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C. <i>Journal of Endocrinology</i> , 2003 , 178, 457-65	4.7	30
101	SEN virus infection in patients with chronic hepatitis C: preferential coinfection with hepatitis C genotype 2a and no effect on response to therapy with interferon plus ribavirin. <i>Journal of Infectious Diseases</i> , 2003 , 187, 307-10	7	17
100	Naturally occurring hepatitis B surface gene variants in chronic hepatitis B virus infection: correlation with viral serotypes and clinical stages of liver disease. <i>Journal of Medical Virology</i> , 2002 , 68, 50-9	19.7	34
99	Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection. <i>Journal of Medical Virology</i> , 2002 , 68, 216-20	19.7	37
98	Early acquisition of TT virus in infants: possible minor role of maternal transmission. <i>Journal of Medical Virology</i> , 2002 , 66, 285-90	19.7	21
97	Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. <i>Hepatology</i> , 2002 , 36, 1416-1424	11.2	26
96	Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2002 , 97, 269-71	7.5	17

95	Molecular epidemiology of hepatitis B viral serotypes and genotypes in taiwan. <i>Journal of Biomedical Science</i> , 2002 , 9, 166-70	13.3	28
94	Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2002 , 37, 283-7	6.9	34
93	Clinical relevance of hepatitis B viral genotypes: a case of d[illegible]vu?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002 , 17, 113-5	4	15
92	Hepatitis B viral genotypes: clinical relevance and molecular characteristics. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002 , 17, 643-50	4	253
91	Hepatitis D virus genotypes in intravenous drug users in taiwan: decreasing prevalence and lack of correlation with hepatitis B virus genotypes. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 3047-9	9.7	30
90	Prevalence and implication of a newly identified infectious agent (SEN virus) in Taiwan. <i>Journal of Infectious Diseases</i> , 2002 , 185, 389-92	7	38
89	Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 1207-9	9.7	154
88	Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 4068-71	9.7	125
87	Clinical and virological aspects of blood donors infected with hepatitis B virus genotypes B and C. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 22-5	9.7	77
86	Paratyphoid hepatitis: an emerging clinical entity. <i>American Journal of Medicine</i> , 2002 , 113, 257-8	2.4	7
85	Hepatitis B viral genotypes and lamivudine resistance. <i>Journal of Hepatology</i> , 2002 , 36, 303-4	13.4	94
84	The effect of interferon plus ribavirin or interferon alone on the development of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2002 , 36, 250	13.4	2
83	Global control of hepatitis B virus infection. <i>Lancet Infectious Diseases, The</i> , 2002 , 2, 395-403	25.5	661
82	Molecular epidemiology of hepatitis B viral serotypes and genotypes in taiwan 2002 , 9, 166		4
81	Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. <i>Hepatology</i> , 2002 , 36, 1416-24	11.2	30
80	Recent research progress in hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2002 , 101, 239-48	3.2	12
79	Post-partum acute exacerbation of chronic hepatitis in a hepatitis C-carrier mother. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001 , 16, 705-8	4	12
78	Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001 , 16, 1001-8	4	37

77	Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. <i>Hepatology</i> , 2001 , 34, 583-9	11.2	47
76	Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus. <i>Hepatology</i> , 2001 , 34, 817-23	11.2	67
75	Relation of Chlamydia pneumoniae infection in Taiwan to angiographically demonstrated coronary artery disease and to the presence of acute myocardial infarction or unstable angina pectoris. <i>American Journal of Cardiology</i> , 2001 , 88, 960-3	3	5
74	Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. <i>Journal of Pediatrics</i> , 2001 , 139, 349-52	3.6	78
73	Mother-to-child HCV transmission. <i>Lancet, The</i> , 2001 , 357, 142-3	4.0	3
72	TT virus infection in patients with chronic hepatitis B or C: influence on clinical, histological and virological features. <i>Journal of Medical Virology</i> , 2000 , 60, 387-92	19.7	22
71	Incidence and clinical presentation of posttransfusion TT virus infection in prospectively followed transfusion recipients: emphasis on its relevance to hepatitis. <i>Transfusion</i> , 2000 , 40, 596-601	2.9	16
70	Low incidence of hepatitis C virus transmission between spouses: a prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000 , 15, 391-5	4	41
69	Efficacy of consensus interferon in the treatment of chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000 , 15, 1418-23	4	9
68	Interspousal transmission of TT virus: Low efficiency and lack of apparent risk factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000 , 15, 1287-1291	4	
67	Effectiveness of second- and third-generation immunoassays for the detection of hepatitis C virus infection in pregnant women. <i>Journal of Obstetrics and Gynaecology Research</i> , 2000 , 26, 265-70		3
66	Hepatitis C virus load during pregnancy and puerperium. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000 , 107, 1503-6	3.7	18
65	Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. <i>Gastroenterology</i> , 2000 , 118, 554-9	13.3	799
64	Hepatitis B genotypes and the response to interferon therapy. <i>Journal of Hepatology</i> , 2000 , 33, 998-1002	13.4	401
63	Interspousal transmission of TT virus: Low efficiency and lack of apparent risk factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000 , 15, 1287-1291	4	
62	Transmission of hepatitis C virus in Asia: past and present perspectives. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000 , 15 Suppl, E91-6	4	59
61	Minimal role of GB virus-C/hepatitis G virus in fulminant and subfulminant hepatitis in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1999 , 14, 352-7	4	14
60	Comparison of two methods for quantification of hepatitis B viral DNA. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1999 , 14, 423-6	4	16

59	GB virus C infection in hemodialysis patients: molecular evidence for nosocomial transmission. <i>Journal of Infectious Diseases</i> , 1999 , 180, 191-4	7	16
58	GB virus-C/hepatitis G virus infection in Taiwan: a virus that fails to cause a disease?. <i>Journal of Biomedical Science</i> , 1999 , 6, 220-5	13.3	9
57	Liver and peripheral blood mononuclear cells are not major sites for GB virus-C/hepatitis G virus replication. <i>Archives of Virology</i> , 1999 , 144, 2173-83	2.6	9
56	Prevalence and implication of TT virus infection: minimal role in patients with non-A-E hepatitis in Taiwan. <i>Journal of Medical Virology</i> , 1999 , 59, 307-12	19.7	31
55	Molecular methods of measurement of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection: implications for occupational health practice. <i>Occupational and Environmental Medicine</i> , 1999 , 56, 730-4	2.1	9
54	Antiandrogen hepatotoxicity in patients with chronic viral hepatitis. <i>European Urology</i> , 1999 , 36, 293-7	10.2	19
53	GB virus-C/hepatitis G virus infection in Taiwan: A virus that fails to cause a disease? 1999 , 6, 220		1
52	Effects of GB virus-C/hepatitis G virus on hepatitis B and C viremia in multiple hepatitis virus infections. <i>Archives of Virology</i> , 1998 , 143, 797-802	2.6	13
51	BRIEF COMMUNICATION: Efficacy of ribavirin plus interferon α on viraemia of GB virus-C/hepatitis G virus: Comparison with interferon α alone. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998 , 13, 1249-1253	4	5
50	Hepatitis C virus infection and chronic active myocarditis. <i>Circulation</i> , 1998 , 98, 1044-5	16.7	4
49	GB virus C/hepatitis G virus infection in patients on continuous ambulatory peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 1998 , 13, 2914-9	4.3	7
48	BRIEF COMMUNICATION: Efficacy of ribavirin plus interferon α on viraemia of GB virus-C/hepatitis G virus: Comparison with interferon α alone. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998 , 13, 1249-1253	4	
47	Blood-bank screening for hepatitis G. <i>Lancet, The</i> , 1997 , 349, 207	4.0	5
46	GB virus-C/hepatitis G virus infection in an area endemic for viral hepatitis, chronic liver disease, and liver cancer. <i>Gastroenterology</i> , 1997 , 112, 1265-70	13.3	67
45	Hepatitis C and G virus infections in polytransfused children. <i>European Journal of Pediatrics</i> , 1997 , 156, 546-9	4.1	23
44	GB virus-C/hepatitis G virus infection in prostitutes: Possible role of sexual transmission. <i>Journal of Medical Virology</i> , 1997 , 52, 381-384	19.7	27
43	Interspousal transmission of GB virus-C/hepatitis G virus: A comparison with hepatitis C virus. <i>Journal of Medical Virology</i> , 1997 , 53, 348-353	19.7	27
42	Hepatitis G virus infection in normal and prospectively followed posttransfusion children. <i>Pediatric Research</i> , 1997 , 42, 784-7	3.2	12

41	Interspousal transmission of GB virus-C/hepatitis G virus: A comparison with hepatitis C virus 1997 , 53, 348		4
40	Rapid hepatic failure associated with a contracted liver mimicking cirrhosis in a case of nasopharyngeal carcinoma with liver metastasis. <i>Liver</i> , 1996 , 16, 283-7		9
39	Hepatitis G virus in intravenous immunoglobulin. <i>Gastroenterology</i> , 1996 , 111, 1399-400	13.3	3
38	Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. <i>Gastroenterology</i> , 1996 , 111, 1307-12	13.3	213
37	Least microtransfusion from mother to fetus in elective cesarean delivery. <i>Obstetrics and Gynecology</i> , 1996 , 87, 244-8	4.9	47
36	GBV-C/HGV infection and aplastic anaemia. <i>Lancet, The</i> , 1996 , 348, 1032-3	40	7
35	GBV-C in the aetiology of fulminant hepatitis. <i>Lancet, The</i> , 1996 , 347, 120-1	40	62
34	Mechanism of vertical transmission of hepatitis G. <i>Lancet, The</i> , 1996 , 347, 1116	40	20
33	Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay. A clinicopathologic study and demonstration of the usefulness of a third-generation assay. <i>Digestive Diseases and Sciences</i> , 1996 , 41, 161-5	4	50
32	Serotyping of hepatitis C virus in chronic type C hepatitis in Taiwan: correlation with genotypes. <i>Journal of Gastroenterology</i> , 1996 , 31, 224-7	6.9	18
31	Absence of extensive genetic heterogeneity of hepatitis C virus in antibody-negative chronic hepatitis C. <i>Journal of Medical Virology</i> , 1996 , 49, 87-90	19.7	7
30	Superinfection by homotypic virus in hepatitis C virus carriers: studies on patients with post-transfusion hepatitis. <i>Journal of Medical Virology</i> , 1996 , 50, 303-8	19.7	24
29	Identification of humoral antigenic determinants in the hepatitis C virus NS3 protein. <i>Journal of Infectious Diseases</i> , 1996 , 174, 173-6	7	13
28	Phylogenetic analysis of GB virus C: comparison of isolates from Africa, North America, and Taiwan. <i>Journal of Infectious Diseases</i> , 1996 , 174, 410-3	7	40
27	Serum hepatitis C virus titers in the progression of type C chronic liver disease. With special emphasis on patients with type 1b infection. <i>Journal of Clinical Gastroenterology</i> , 1996 , 23, 280-3	3	7
26	Prominent proliferative response of peripheral blood mononuclear cells to a recombinant non-structural (NS3) protein of hepatitis C virus in patients with chronic hepatitis C. <i>Clinical and Experimental Immunology</i> , 1995 , 101, 272-7	6.2	9
25	Quasispecies of hepatitis C virus and genetic drift of the hypervariable region in chronic type C hepatitis. <i>Journal of Infectious Diseases</i> , 1995 , 172, 261-4	7	39
24	Prevalence, genotypes and antibody titer of hepatitis C virus in pregnant women in Taiwan. <i>Journal of Obstetrics and Gynaecology (Tokyo, Japan)</i> , 1995 , 21, 557-62		4

23	Evaluation of third-generation hepatitis C antibody assay in chronic hepatitis C and chronic non-B, non-C hepatitis. <i>Viral Immunology</i> , 1995 , 8, 135-9	1.7	1
22	. <i>Journal of Pediatrics</i> , 1995 , 127, 671	3.6	1
21	Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. <i>Journal of Pediatrics</i> , 1995 , 126, 589-91	3.6	148
20	Genotypes of hepatitis C virus in Taiwan and the progression of liver disease. <i>Journal of Clinical Gastroenterology</i> , 1995 , 21, 233-7	3	47
19	Intrafamilial transmission of hepatitis C virus in hemodialysis patients. <i>Journal of Medical Virology</i> , 1995 , 45, 381-5	19.7	30
18	Hepatitis C virus infection in pregnant women: detection by different anti-HCV immunoassays and serum HCV-RNA. <i>Asia-Oceania Journal of Obstetrics and Gynaecology</i> , 1994 , 20, 13-8		2
17	Detection of Divergent Hepatitis C Virus Envelope Sequences. <i>Journal of Biomedical Science</i> , 1994 , 1, 158-162	13.3	
16	Possible role of high-titer maternal viremia in perinatal transmission of hepatitis C virus. <i>Journal of Infectious Diseases</i> , 1994 , 169, 638-41	7	134
15	Mixed infections of hepatitis C virus as a factor in acute exacerbations of chronic type C hepatitis. <i>Journal of Infectious Diseases</i> , 1994 , 170, 1128-33	7	63
14	Detection of Divergent Hepatitis C Virus Envelope Sequences. <i>Journal of Biomedical Science</i> , 1994 , 1, 158-162	13.3	3
13	Immune response to a hepatitis C virus nonstructural protein in chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 1994 , 21, 403-11	13.4	24
12	A clinicopathologic study of chronic non-A, non-B (type C) hepatitis in Taiwan: comparison between posttransfusion and sporadic patients. <i>Journal of Hepatology</i> , 1994 , 21, 244-9	13.4	34
11	Sexual transmission of HCV. <i>Lancet, The</i> , 1993 , 342, 626	40	8
10	Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis. <i>Gastroenterology</i> , 1993 , 105, 583-7	13.3	83
9	Comparison of Three Different Immunoassays and PCR for the Detection of Hepatitis C Virus Infection in Pregnant Women in Taiwan. <i>Vox Sanguinis</i> , 1993 , 65, 117-121	3.1	11
8	Low prevalence of hepatitis C virus infection among dentists in Taiwan. <i>Journal of Medical Virology</i> , 1993 , 40, 10-3	19.7	23
7	Comparison of three different immunoassays and PCR for the detection of hepatitis C virus infection in pregnant women in Taiwan. <i>Vox Sanguinis</i> , 1993 , 65, 117-21	3.1	8
6	Immunoglobulin M antibodies against hepatitis C virus antigens: significance and applications. <i>Gastroenterologia Japonica</i> , 1993 , 28 Suppl 5, 67-70		0

5	Intrafamilial transmission of hepatitis C virus: the important role of infections between spouses. <i>Journal of Infectious Diseases</i> , 1992 , 166, 900-3	7	134
4	Transient immunoglobulin M antibody response to hepatitis C virus capsid antigen in posttransfusion hepatitis C: putative serological marker for acute viral infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992 , 89, 5971-5	11.5	52
3	Overview of Hepatitis B and C Viruses313-330		24
2	Control by Vaccination: Asian and Taiwan Experience18-23		
1	NAFLD in Chinese and South Asian people206-216		